The trend toward hyaluronic acid injectables may be part of the reason that collagen fillers will be gone from the U.S. market at year’s end, reports the latest issue of Dermatology Times.
In late 2009, Johnson & Johnson announced that it was discontinuing its collagen filler Evolence, and in January 2010 Allergan announced it would be discontinuing its collagen line of fillers at the end of the year. Allergan actually halted production of its collagen products in 2009, but manufactured sufficient inventory to meet estimated market demand through the end of 2010, according to Kelly Lao, manager of corporate communications.
“The discontinuation of the sale of our collagen products … is in response to declined market interest … since the introduction of hyaluronic acid dermal fillers like Juvéderm have become more popular,” Ms. Lao says.
“There is an overwhelming popularity of the new kid on the block: the hyaluronic acids. They have been embraced universally, and suddenly collagens aren’t as popular,” concurs Dr. Seth L. Matarasso, a clinical professor of dermatology at the University of California School of Medicine, San Francisco
The popularity of hyaluronic acid products is due to several factors:
- Longer-lasting results
- Appear to give a better fill
- Some contain lidocaine for less painful injections
- Upcoming improvements will provide more volume and contour-changing ability and the ability to fill deeper lines
Hyaluronic acids products include Restylane, Juvéderm, Radiesse, which are all available at Will Surgical Arts in the Frederick County area in Maryland.
“Dermatologists prepare for departure of collagen from U.S. market” is online at Modern Medicine.
last week during the World Congress for Anti-Aging Medicine in Monaco. The new line of products is said to contain the same patented NASHA technology used in Restylane injectable filler, which they say adds a pleasing consistency while preserving moisture and luster in the skin.
Botox may be used to relieve migraine headaches, according to new research published in Archives of Dermatology. Botox injections “at doses appropriate for cosmetic purposes may be sufficient to prevent migraine attacks” concluded authors of the study.
will be advertised as a more comfortable, yet equally effective alternative to other wrinkle filler treatments. Containing 0.3% lidocaine makes the treatment area numb very quickly, possibly decreasing the need for topical anesthetic.
A news station in Ohio recently aired 
Pharmaceutical co. Allergan Inc’s recently filed suit against the Food and Drug Administration contends that marketing restrictions placed on off-label 
